Cell Therapeutics (CTIC) Receives EU Approval for Pixuvri as Monotherapy to Treat Relapsed/Aggressive Non-Hodgkin B-Cell Lymphomas
Tweet Send to a FriendGet Alerts CTIC Hot Sheet
Up)
Trade CTIC Now!
Cell Therapeutics (Nasdaq: CTIC) announces Pixuvri approved in EU as monotherapy to treat adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-Cell Lymphomas.
The decision allows CTI to market Pixuvri in the 27 Member States of the EU as well as in Iceland, Liechtenstein and Norway. CTI expects to make Pixuvri immediately available in the EU, initially through a named patient program. CTI plans to market and commercialize Pixuvri with its own sales force in the EU starting in the 2nd half of 2012.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The decision allows CTI to market Pixuvri in the 27 Member States of the EU as well as in Iceland, Liechtenstein and Norway. CTI expects to make Pixuvri immediately available in the EU, initially through a named patient program. CTI plans to market and commercialize Pixuvri with its own sales force in the EU starting in the 2nd half of 2012.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- CTI Announces New Data Presented at EHA 2013 Congress Demonstrating the Safety and Tolerability Profile of Pacritinib in Patients with Myelofibrosis
- Rambus (RMBS) Enters License with STMicro (STM)
- Kodak (EKDKQ) Asks Court to Approve $406M Rights Offering on Bankruptcy Emergence
Create E-mail Alert Related Categories
Corporate News, Hot Corp. News, Trading Halts
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
